CGP42112: the full AT2 receptor agonist and its role in the renin–angiotensin–aldosterone system: no longer misunderstood

Yazmin M. Restrepo1, Natalia M. Noto1 and Robert C. Speth1,2
1Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, U.S.A.; 2Department of Physiology and Pharmacology, School of Medicine, Georgetown University, Washington, DC 20007, U.S.A.

For years, the AT2R-selective ligand CGP42112 has been erroneously characterized as a partial agonist, partly due to its ability to also interact with the AT1R at high concentrations. As late as 2009, it was still being characterized as an antagonist as well. In this perspective/opinion piece, we try to resolve the ambiguity that surrounds the efficacy of this compound by extensively reviewing the literature, tracing its beginnings to 1989, showing that CGP42112 has never been convincingly shown to be a partial agonist or an antagonist at the AT2R. While CGP42112 is now routinely characterized as an AT2R agonist, regrettably, there is a paucity of studies that can validate its efficacy as a full agonist at the AT2R, leaving the door open for continuing speculation regarding the extent of its efficacy. Hopefully, the information presented in this perspective/opinion piece will firmly establish CGP42112 as a full agonist at the AT2R such that it can once again be used as a tool to study the AT2R.

CGP42112 is a peptidomimetic compound [1] that functions as an angiotensin II type 2 receptor (AT2R)-selective ligand. It has a long and complex history of differential characterization, surrounded by much ambiguity and uncertainty. A PubMed search of the word ‘CGP42112’ on July 12, 2022 found a total of 329 publications. Another 20 publications were found as derivatives of the original search. Among these manuscripts, there are many that contribute to the ambiguity that surrounds CGP42112’s efficacy. They can be divided into two groups: one of research papers, which present data to demonstrate or infer antagonistic, partial agonistic or full agonistic classifications at the AT2R, and another group of review papers or research studies that did not directly investigate CGP42112 but contribute to the ambiguity indirectly (by citing other authors) or by merely presenting the concept of partial agonism or antagonism without substantiation. We selected 196 of these papers as representative of the categorization of the efficacy of CGP42112 at the AT2R. We did not cite every paper that had CGP42112 in its text as many papers are reviews of the entire renin–angiotensin–aldosterone system (RAAS) and CGP42112 actions at the AT2R were not a major focus of such papers.

First discovered by Whitebread et al. at Ciba-Geigy in 1989, CGP42112 was originally developed to be an angiotensin (Ang) II receptor antagonist (Supplementary Table S1). However, the present study did not assess the efficacy of CGP42112, as it simply showed it to be a selective ligand of the Ang II receptor subtype ‘A’ (now known as the AT2R) [2]. However, 11 of the 89 citations, which we include in Supplementary Table S1, cite it as the basis for characterizing CGP42112 as an antagonist. A subsequent report [3] which characterized CGP42112 as an antagonist of the ‘angiotensin IIIB receptor subtype’ (now known as the angiotensin II type 1 receptor, AT1R) may have also added to the perception that CGP42112 was an AT2R antagonist. It is noteworthy that the 1991 ‘Report of the Nomenclature Committee of the Council for High Blood Pressure Research: Nomenclature for Angiotensin Receptors’ reported that CGP42112A was an AT2R antagonist, but with a caveat that until an established functional response mediated by the AT2R was established, that it was not possible to make a definitive determination of its efficacy. Indeed, this
caveat was present when the functional response of the AT\(_2\)R as a physiological antagonist of the AT\(_1\)R was recognized, such that the antagonism of AT\(_1\)R mediated responses by CGP42112 could be recognized as an AT\(_2\)R agonist response. Later, it was shown to be an AT\(_2\)R agonist mediating an inhibition of T-type calcium channels that mimicked that of Ang II in cells expressing only AT\(_2\)R, strongly suggesting that it was a full agonist but not providing definitive data [4]. In 1993, some of these same investigators [5] did characterize CGP42112 as a full AT\(_2\)R agonist showing it to be equiefficacious with Ang II at decreasing cyclic guanosine monophosphate (cGMP) levels by inhibiting particulate guanylate cyclase, and years later Widdop et al. confirmed the full agonism of CGP42112 at the AT\(_2\)R [6]. This should have been the definitive characterization of the efficacy of CGP42112 as a full agonist, despite its initial characterization as an antagonist. However, as noted below, sometime later the characterization of CGP42112 began to be misconstrued (Supplementary Tables S1 and 2). Different papers started referring to CGP42112 as an antagonist of the AT\(_2\)R (Supplementary Table S1), or as a partial agonist or a partial antagonist of the AT\(_2\)R (Supplementary Table S2), leading to the uncertainty that still surrounds the characterization of this compound.

**AT\(_2\)R signaling and functionality**

The AT\(_2\)R is well characterized structurally as a G-protein-coupled receptor (GPCR) that is abundantly present during the fetal development, but has reduced expression during adult life, when the AT\(_1\)R becomes predominant [7–9]. While the AT\(_1\)R mediates most of the physiological and pathophysiological effects of Ang II in tissues such as vascular smooth muscle, endothelium, heart and kidney [10], the AT\(_2\)R is thought to oppose its effects by inhibiting cell proliferation and differentiation, promoting vasodilation, while reducing inflammation and oxidative stress [11,12]. Under controlled conditions, when AT\(_1\)R function is blocked, stimulation of the AT\(_2\)R by Ang II lowers blood pressure [13,14], and causes vasodilation [15], although these effects are not observed in all studies [16,17]. Thus, the physiological significance of the AT\(_2\)R is still not fully understood, contributing to its ambiguity and that of CGP42112 as an AT\(_2\)R agonist.

What is known so far is that there are a variety of signaling pathways for the AT\(_2\)R. Some of the AT\(_2\)R signaling pathways are reported to involve the G\(_{i/o}\) protein [18–20], or an unspecified G protein that is not G\(_{i/o}\) [21], while others appear to be G protein independent [22–25]. Main pathways include stimulation of several phosphatases; stimulation of bradykinin formation [26], which activates B\(_2\) bradykinin receptors [27], which activates nitric oxide synthase (NOS), leading to cGMP formation; inhibition of particulate guanylate cyclase activity via phosphotyrosine phosphatase (PTP) activation [23], heterodimerization with AT\(_2\) receptors to inhibit their function [28], as well as heterodimerization with the bradykinin B\(_2\) receptor [29] (Figure 1). Additionally, the AT\(_2\)R has been reported to both activate [30–32] and inhibit [33,34] nuclear factor kappa B (NF-kB) signaling. Ruiz-Ortega et al. [35] also stated that CGP42112 acted upon the AT\(_2\)R to stimulate NF-kB signaling; however, they used 10 \(\mu\)M CGP42112 so it is not possible to reach any conclusions regarding its actions as an AT\(_2\)R agonist or antagonist from this study. Noting the ambiguities regarding the agonistic and antagonistic properties for which CGP42112 has been attributed, Rompe et al. [33] stated ‘Both features rendered CGP42112A a problematic tool for research and prevented its development for clinical use’.

Finally, AT\(_2\)R activation can result in tissue remodeling leading to apoptosis, inhibition of hyperplasia in pathological situations, and reduction of cardiac inflammation and fibrosis [11,36,37].

**Mischaracterization of CGP42112**

As seen in the literature, CGP42112 is referred to by three different names: CGP42112, CGP42112A, or GP42112B. The ‘A’ and ‘B’ versions of this compound indicate different salt forms. CGP42112A refers to the hydrochloride salt, while CGP42112B represents the trifluoroacetate salt [38]. However, there is likely minimal differential pharmacological effects between these two salt forms of CGP42112.

The uncertainty that surrounds the classification of CGP42112 increased when publications started referring to it as a partial agonist of the AT\(_2\)R. Although it is hard to pinpoint the exact time when this mischaracterization began, our research dates it back to 1993, when Timmermans et al. wrote a review and stated that CGP42112A possessed partial agonistic effects due to it being a modified peptide but did not provide any data or citations proving such [10]. Macari et al. also published the concept as a possibility, but again, without supporting data [39]. Based upon their expertise and strong reputation in the RAAS field, their postulation was taken as fact, whereupon later publications started to incorrectly refer to the compound as a partial agonist of the AT\(_2\)R (Supplementary Table S2). However, based on empirical studies that looked at the agonistic properties of CGP42112, noted above, there is evidence showing that it is in fact a full agonist of the AT\(_2\)R [5,6,15], which is consistent with other papers that interpret it as a full agonist.
Figure 1. Activation and inhibition of AT1 and AT2 Ang II receptors

The pharmacology and signaling pathways of the AT1R are well established [51] and not described in this figure, which instead focuses on several of the proposed pharmacology and signaling pathways of the AT2R. Agonist ligands for the AT2R shown in the figure are Ang II and III, as well as CGP42112. Not shown are three other AT2R selective agonists; compound 21 [C21] [52], ß-Pro7 Ang III [15], and pNH2Phe6Ang II [32,35,53]. The putative pathways shown are from Brechler et al. inhibition of particulate guanylyl cyclase via tyrosine phosphatase in a G protein-independent manner [23], increased production of NO and cGMP by direct activation of NOS and soluble guanylate cyclase [54], via stimulation of bradykinin formation [26,55], which stimulates B2 bradykinin receptor mediated eNOS activation, formation of NO which stimulates synthesis of cyclic guanosine monophosphate (cGMP) by soluble guanylate cyclase [27], or with subsequent activation of the B2 receptor; and via dimerization of AT2R and bradykinin B2 receptor which also increases NO synthesis and cGMP formation [29], and heterodimerization with the AT1R to inhibit its function [56].

*Signaling pathways have been reported to be both G protein-dependent and G protein-independent.
based on the near equivalency of the responses to CGP42112 and Ang II at concentrations that give a near maximal response [4,40].

Yet another factor that may contribute to the ambiguity of agonism of CGP42112 at the AT2R is cell type-specific responses. Thus, the different responses mediated by AT2R on NG108-15, N1E-115, PC12W, NIH 3T3 fibroblasts, neonatal rat neurons, rabbit proximal tubule epithelial cells, and AT2R transfected cells is another confounder in characterizing the agonistic effects of CGP42112. The extreme example of antithetical AT2R signaling is the report that AT2R in NIH3T3 cells [24] and PC12W cells (specifically CGP42112) [41] can both stimulate and inhibit ERK1/2 depending on whether the cells are quiescent or stimulated by nerve growth factor (NGF), respectively.

Another source of the misconception that CGP42112 is a partial agonist is the misinterpretation of the concentration response curve (CRC) of CGP42112 relative to that of Ang II by Hansen et al. [19]. Despite showing an arbitrary maximum response of 100% of 35S-GTPγS incorporation to both Ang II and CGP42112 at concentrations up to 1 μM, a reduction in the response at 10 μM CGP42112 probably led Hansen et al., to mischaracterize CGP42112 as a partial agonist.

Further adding to the misconception of the efficacy of CGP42112 is that while a potent agonist at the AT2R, it does not interact significantly with the AT1R until its concentration approaches the micromolar range. Thus, part of the reason for the mischaracterization seems to involve the role of CGP42112 at different concentrations. It has been reported that at low concentration (typically nM) [42], the compound functions as an agonist, but as the concentration increases (typically μM and above), it gains antagonistic properties at the AT1R [38], which is where some of the confusion lies. As concentration increases, the empirical studies mentioned above show that CGP42112 remains a full agonist at the AT2R, while it also begins to bind to the AT1R, acting in an antagonistic manner [3,38,43].

A comparison between two papers by Macari et al. reveals a major inconsistency in their classification of CGP42112 [38,39]. As noted above, Macari et al. characterized CGP42112 as a weak AT1R antagonist [38]. However, upon blockade of the RAAS with an angiotensin-converting enzyme (ACE) inhibitor, CGP42112 was reported to gain partial agonistic properties at the AT1R [39] completely contradicting the conclusion of their 1993 paper, with respect to the efficacy of CGP42112 at the AT1R. With the supposition in mind, that CGP42112 was a partial agonist at the AT1R, Macari et al. suggested that the same might be true at the AT2R [39]. Based upon the way in which the experiments were conducted, it is believed that the interpretation of the 1994 experiment was flawed, since it utilized losartan to saturate the AT1R, precluding any effects of CGP42112B on the AT1R, as it would have been unable to bind to it. This contradicts the findings from their 1993 paper, where they stated that CGP42112B acts as an AT1R antagonist at higher concentrations when the RAAS is not inhibited. Since the conditions at which each experiment was conducted are different, an exact classification of the compound based upon the comparison of the two studies cannot be achieved. Further complicating matters, there is a single report of CGP42112 acting as an antagonist of Ang II at the AT1R [44]. The concentrations of CGP42112 used in that study were 0.1 to 1 μM, opening up the possibility that the agonistic effects were occurring at the AT1R. Additionally, they state in their manuscript, ‘In addition, 10−6 M of the peptide AT2 antagonist CGP-42112A with some agonistic properties was also used’, without providing any citation. Of note, these authors also used the classical AT1R antagonist, PD123319, to block activation of their AT1R-mediated response.

CGP42112 is a full agonist at the AT2R

As of 2021 (based on our ‘CGP42112’ PubMed search), CGP42112 has most recently been consistently referred to as an AT1R agonist. However, in most cases, a full dose-response curve comparison with Ang II was not done (Supplementary Table S3), so no conclusion as to whether CGP42112 is a full agonist can be made from such studies. Nonetheless, the definitive studies of Brechler et al. [5] and Widdop et al. [6] showing equivalent AT2-agonist efficacy CRCs of Ang II and CGP42112 along with the near identical CRCs of Ang III and CGP42112 reported by Del Borgo et al. [15]; the anomalous concentration response data for CGP42112 showing equipotency as an AT2 agonist with Ang III [19]; the near identical maximal agonist responses of Ang II and CGP42112 at the AT2R [4,40]; the absence of any empirical data showing partial agonism of CGP42112 at the AT2R, together provide compelling evidence that CGP42112 is a full agonist.

Perspective

This analysis strives to remove the stigma of CGP42112’s mischaracterization as a partial agonist. This ambiguity has caused CGP42112 to fall out of favor as a tool to study the importance of the AT2R in the RAAS. Compound 21 (C21), which has yet to be shown to have a clinical application, has been used in nearly 200 studies (40 of which were reported between 2020 and 2022) using the search terms ‘C21 and AT2’, or ‘compound 21 and AT2’, or ‘C21 and
angiotensin,’ or ‘compound 21 and angiotensin,’ in PubMed, while CGP42112 has only been reported to have been used once each in 2020 and 2021, with no publications so far in 2022 using the search terms ‘CGP42112 and AT2,’ or ‘CGP42112 and angiotensin,’ in PubMed.

Prior to its virtual abandonment as a tool to study AT2R function, CGP42112 was used to show that AT2R stimulation can further lower blood pressure when used in combination with an AT1R antagonist [13,14] and that the AT2R promotes natriuresis [45]. Given that Lee et al. showed that CGP42112 had neuroprotective effects mediated by the AT2R while C21 was ineffective as a neuroprotectant [46], necessitates correct characterization of CGP42112 as a full AT2R agonist so that it can continue to be used to assess the receptor’s functionality in concert with other AT2R agonists and antagonists [47–49].

An additional concern for the use of CGP42112 as a tool to study the RAAS has been that it is a peptide, in contrast with C21, which is a small molecule that can be administered orally. However, development of novel formulations of peptide drugs using nanotechnology has enabled their administration in oral forms with increased in vivo stability and bioavailability [50]. Thus, CGP42112, by virtue of its greater potency as an AT2R agonist, can serve as a more powerful AT2R agonist as well as an alternative to C21. To avoid the risk of confounding by an idiosyncratic action of a single AT2R agonist, future studies should use multiple AT2R agonists to better understand the function of the AT2R.

It is critical to revisit previous reports that mischaracterized CGP42112 to eliminate some of the ambiguities that have plagued our ability to fully appreciate AT2R’s function in the RAAS.

Data Availability
N/A

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
This work was supported by NIH-NINDS [grant number R01-NS124204 (to Yazmin M. Restrepo and Robert C. Speth)].

CRediT Author Contribution
Yazmin M. Restrepo: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing—original draft, Writing—review & editing. Natalia M. Noto: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing—original draft, Writing—review & editing. Robert C. Speth: Conceptualization, Formal analysis, Supervision, Writing—original draft, Writing—review & editing.

Acknowledgements
Figure 1 was created under a license from BioRender.com. Dr Stephen Whitebread provided useful background information to the authors. Dr Kathryn Sandberg provided helpful suggestions for manuscript content.

Abbreviations
ACE, angiotensin-converting enzyme; Ang, angiotensin; AT1R, angiotensin II type 1 receptor; AT2R, angiotensin II type 2 receptor; cGMP, cyclic guanosine monophosphate; CRC, concentration response curve; eNOS, endothelial nitric oxide synthase; GPCR, G-protein-coupled receptor; NF-κB, nuclear factor κB; NGF, nerve growth factor; NOS, nitric oxide synthase; PTP, phosphotyrosine phosphatase; RAAS, renin–angiotensin–aldosterone system.

References
1 Wang, Y., Han, L., Shen, M., Jones, E.S., Spizzo, I., Walton, S.L. et al. (2020) Serelaxin and the AT(2) receptor agonist CGP42112 evoked a similar, nonadditive, cardiac antifibrotic effect in high salt-fed mice that were refractory to candesartan cilexetil. ACS Pharmacol. Transl. Sci. 3, 76–87, https://doi.org/10.1021/acsptsci.9b00095
2 Whitebread, S., Mele, M., Kamber, B. and de Gasparo, M. (1989) Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. 163, 284–291, https://doi.org/10.1016/0006-291X(89)92133-5
3 Criscione, L., Thomann, H., Whitebread, S., de Gasparo, M., Buhimayer, P., Herold, P. et al. (1990) Binding characteristics and vascular effects of various angiotensin II antagonists. J. Cardiovasc. Pharmacol. 16, S56–S59, https://doi.org/10.1097/00005344-199016004-00012
4 Buisson, B., Bottari, S.P., de Gasparo, M., Gallo-Payet, N. and Payet, M.D. (1992) The angiotensin AT2 receptor modulates T-type calcium current in non-differentiated NG108-15 cells. FEBS Lett. 309, 161–164, https://doi.org/10.1016/0014-5793(92)81086-2

© 2022 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
33 Rompe, F., Artuc, M., Hallberg, A., Alterman, M., Stroder, K., Thöne-Reinecke, C. et al. (2010) Direct angiotensin II Type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor (kappa)B. *Hypertension*, https://doi.org/10.1161/HYPERTENSIONAHA.109.147843

34 Wu, L., Iwai, M., Li, Z., Shiuchi, T., Min, L.J., Cui, T.X. et al. (2004) Regulation of inhibitory protein-kappabB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. *Mol. Endocrinol.* 18, 666–678

35 Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Konig, S., Wittig, B. and Egido, J. (2000) Angiotensin II activates nuclear transcription factor kappabB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. *Circ. Res.* 86, 1266–1272

36 Matsubara, H. (1998) Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. *Circ. Res.* 83, 1182–1191, https://doi.org/10.1161/01.RES.83.12.1182

37 Namsoleck, P., Recarti, C., Fouquier, S., Steckelings, U.M. and Unger, T. (2014) AT(2) receptor and tissue injury: therapeutic implications. *Curr. Hypertens. Rep.* 16, 416, https://doi.org/10.1007/s11906-013-0416-6

38 Macari, D., Bottari, S., Whitebread, S., de Gasparo, M. and Levens, N. (1993) Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat. *Eur. J. Pharmacol.* 249, 85–93, https://doi.org/10.1016/0014-2999(93)90665-5

39 Macari, D., Whitebread, S., Cumin, F., de Gasparo, M. and Levens, N. (1994) Renal actions of the angiotensin AT2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. *Eur. J. Pharmacol.* 259, 27–36, https://doi.org/10.1016/0014-2999(94)90153-8

40 Israel, A., Stromberg, C., Tsutsuji, K., Garrido, M.D., Torres, M. and Saavedra, J.M. (1995) Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. *Brain Res. Bull.* 38, 441–446, https://doi.org/10.1016/0361-9230(95)00111-F

41 Stroth, U., Blume, A., Mielke, K. and Unger, T. (2000) Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. *Brain Res. Mol. Brain Res.* 78, 175–180, https://doi.org/10.1016/S0169-328X(00)00093-0

42 Ozawa, Y., Suzuki, Y., Murakami, K. and Miyazaki, H. (1996) The angiotensin II type 2 receptor primarily inhibits cell growth via pertussis toxin-sensitive G proteins. *Biochem. Biophys. Res. Commun.* 228, 328–333, https://doi.org/10.1006/bbrc.1996.1661

43 Hines, J., Heerding, J.N., Fluharty, S.J. and Yee, D.K. (2001) Identification of angiotensin II type 2 (AT2) receptor domains mediating high-affinity CGP 42112A binding and receptor activation. *J. Pharmacol. Exp. Ther.* 298, 665–673

44 Wolf, G., Ziyadeh, F.N., Thaiss, F., Tomaszewski, J., Caron, R.J., Wenzel, U. et al. (1997) Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. *J. Clin. Invest.* 100, 1047–1058, https://doi.org/10.1172/JCI119615

45 Hakam, A.C. and Hussain, T. (2005) Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. *Hypertension* 45, 270–275, https://doi.org/10.1161/01.HYP.0000151622.47814.6f

46 Lee, S., Brait, V.H., Arumugam, T.V., Evans, M.A., Kim, H.A., Widdop, R.E. et al. (2012) Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. *Exp. Transl. Stroke Med.* 4, 16, https://doi.org/10.1186/2040-7378-4-16

47 Hallberg, M., Sumners, C., Steckelings, U.M. and Hallberg, A. (2018) Small-molecule AT2 receptor agonists. *Med. Res. Rev.* 38, 602–624, https://doi.org/10.1002/med.21449

48 Smith, M.T., Anand, P. and Rice, A.S.C. (2016) Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies. *Pain* 157, S23–S41, https://doi.org/10.1097/J.pain.0000000000000369

49 Isaksson, R., Lindman, J., Wannberg, J., Sallander, J., Backlund, M., Baraldi, D. et al. (2019) A series of analogues to the AT(2)R prototype antagonist C38 allow fine tuning of the previously reported antagonist binding mode. *Chemistry Open* 8, 114–125, https://doi.org/10.1002/open.201800282

50 Haddadzadegan, S., Dorkoosh, F. and Bernkop-Schnürch, A. (2022) Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers. *Adv. Drug Deliv. Rev.* 182, 114097, https://doi.org/10.1016/j.addr.2021.114097

51 Miura, S., Saku, K. and Karnik, S.S. (2003) Molecular analysis of the structure and function of the angiotensin II type 1 receptor. *Hypertens. Res.* 26, 937–943, https://doi.org/10.1259/hypres.26.937

52 Wan, Y., Wallinder, C., Plouffe, B., Beaudry, H., Mahalingam, A.K., Wu, X. et al. (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. *J. Med. Chem.* 47, 9995–9008, https://doi.org/10.1021/jm049715t

53 Speith, R.C. and Kim, K.H. (1990) Discrimination of two angiotensin II receptor subtypes with a selective analogue of angiotensin II, p-aminophenylalanine 6 angiotensin II. *Biochem. Biophys. Res. Commun.* 169, 997–1006, https://doi.org/10.1016/0006-291X(90)91993-3

54 Abadir, P.M., Carey, R.M. and Siragy, H.M. (2003) Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. *Hypertension* 42, 600–604, https://doi.org/10.1161/01.HYP.0000090323.38122.5C

55 Gohtke, P., Pees, C. and Unger, T. (1998) AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. *Hypertension* 33, 349–355, https://doi.org/10.1161/01.HYP.33.3.349

56 Miura, S., Matsuo, Y., Kiya, Y., Karnik, S.S. and Saku, K. (2010) Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. *Biochem. Biophys. Res. Commun.* 391, 85–90, https://doi.org/10.1016/j.bbrc.2009.11.008